Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Questionnaire: Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.

Study summary

There are no prospective studies of pregnancies for the diseases studied here in (Heredity Hemorrhagic Telangiectasia, Marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and cerebro-spinal arteriovenous malformations) although complications of these can present life-threatening health problems for the mother and her baby.

The purpose of this National prospective study is to obtain greater insight into obstetrical complications associated with rare maternal vascular genetic disorders in order to improve prevention and to reduce risk of death.

In this context, experts and patient associations consider that there is a need to make real progress in the formulation of recommendations based on scientific data.

Eligibility

Primary outcome measure(s)

• Occurrence of obstetrical complications among patients with rare vascular anomalies. — Every 3 months up to 21 months
  The primary outcome measure is the occurrence of specific and serious obstetrical complications during the pregnancy period and and after 12 months among patients with rare vascular anomalies, obtained via phone questionnaire.

Trial sites (37)

More Hospices Civils de Lyon trials in France

Other trials for the same condition